Trial Profile
Prospective signal study of Imetelstat in patients with refractory anemia with ring sideroblasts with (RARS-T) or without (RARS) thrombocytosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Feb 2016
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary)
- Indications Sideroblastic anaemia
- Focus Adverse reactions; Pharmacogenomic
- 25 Feb 2016 According to a Geron Corporation media release, results for safety and efficacy from this study were presented at the 57th American Society of Hematology annual meeting.
- 10 Nov 2015 According to a Geron Corporation media release, results from this study will be presented at the 57th American Society of Hematology annual meeting
- 09 Nov 2015 New trial record